Drug Profile

ACT 1004 1239

Alternative Names: ACT-1004-1239

Latest Information Update: 25 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Idorsia Pharmaceuticals
Class Antineoplastics; Immunotherapies; Small molecules
Mechanism of Action CXCR7 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Multiple sclerosis
No development reported Cancer
Discontinued Immunological disorders

Most Recent Events

25 Feb 2026 ACT 1004 1239 is still in preclinical development in Multiple-sclerosis in Switzerland (PO) (Idorsia pipeline, February 2026)
28 Nov 2025 No recent reports of development identified for phase-I development in Cancer(In volunteers) in Portugal (PO, Capsule)
30 Oct 2025 Idorsia pharmaceuticals plans proof-of-concept study in multiple sclerosis (PO) in Q1 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com